Effect of Vitamin D3 Supplementation on Symptomatic Uterine Fibroid in Women With Vitamin D Deficiency

Launched by NAHIDA AKTER · May 31, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether taking vitamin D3 can help women who have uterine fibroids and are also low in vitamin D. Uterine fibroids are non-cancerous growths in the uterus that can cause symptoms like heavy menstrual bleeding and frequent urination. The study will involve 39 women aged 18 to 50 who have been diagnosed with uterine fibroids and have low levels of vitamin D. Participants will take vitamin D3 supplements for six months, and then their symptoms and the size of their fibroids will be checked again to see if there has been any improvement.

To be eligible for the trial, women must be generally healthy and not currently pregnant or breastfeeding. They also should not be taking any hormonal treatments or other supplements that could interfere with the study. Throughout the trial, participants will need to attend follow-up visits and complete some assessments. If you're interested in helping researchers understand how vitamin D3 might affect uterine fibroids, this could be a great opportunity.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • .Women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period.
• • Women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound.
• • Serum 25-hydroxyvitamin D \[25(OH)D\] levels below 20 ng/mL (indicating vitamin D deficiency).
• • Presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency).
• • Participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases).
• • Willingness to provide written informed consent for participation in the study.
• • No current use of hormonal therapy, other vitamin D supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens).
• • Participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests.
• Exclusion Criteria:
• • Women younger than 18 or older than 50 years.
• • Serum 25-hydroxyvitamin D \[25(OH)D\] levels of 20 ng/mL or higher.
• • Women without a confirmed diagnosis of uterine fibroids (leiomyoma) through imaging.
• • Pregnant or breastfeeding women, or those planning to conceive during the study period.
• • Presence of chronic illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease that could interfere with the study's outcomes.
• • Current or recent use of hormonal therapy, other vitamin D supplements, or medications that affect calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens).
• • Women who have undergone surgical interventions (e.g., myomectomy, hysterectomy) or other medical treatments specifically for uterine fibroid within the past 6 months.
• • Women with conditions like hyperparathyroidism or calcium disorders that might affect vitamin D metabolism or fibroid growth.